Mount Yale Investment Advisors LLC Invests $152,000 in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Mount Yale Investment Advisors LLC bought a new stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATECFree Report) during the 4th quarter, Holdings Channel.com reports. The firm bought 16,526 shares of the medical technology company’s stock, valued at approximately $152,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its stake in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 4,234 shares in the last quarter. Ballentine Partners LLC acquired a new position in Alphatec during the 4th quarter worth approximately $120,000. Courier Capital LLC boosted its holdings in Alphatec by 76.9% in the 4th quarter. Courier Capital LLC now owns 69,000 shares of the medical technology company’s stock worth $633,000 after acquiring an additional 30,000 shares during the period. Franklin Resources Inc. grew its position in Alphatec by 299.3% in the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock valued at $343,000 after acquiring an additional 48,308 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock valued at $948,000 after purchasing an additional 133,653 shares during the period. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Stock Performance

Shares of ATEC stock opened at $12.06 on Thursday. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $17.34. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -9.42 and a beta of 1.41. The company’s 50-day simple moving average is $10.05 and its 200-day simple moving average is $8.10.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Finally, Needham & Company LLC boosted their price target on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.56.

Check Out Our Latest Analysis on ATEC

Insider Buying and Selling

In other Alphatec news, EVP David Sponsel sold 58,283 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the transaction, the executive vice president now directly owns 502,311 shares of the company’s stock, valued at $5,379,750.81. The trade was a 10.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Patrick Miles sold 6,687 shares of Alphatec stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total value of $80,244.00. Following the sale, the chief executive officer now directly owns 5,501,715 shares in the company, valued at approximately $66,020,580. This trade represents a 0.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 65,208 shares of company stock worth $706,835 over the last ninety days. 22.80% of the stock is owned by insiders.

Alphatec Company Profile

(Free Report)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Recommended Stories

Want to see what other hedge funds are holding ATEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alphatec Holdings, Inc. (NASDAQ:ATECFree Report).

Institutional Ownership by Quarter for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.